Contents

Search

ixabepilone (BMS-247550)

Indications: - metastatic breast cancer Contraindications: - hepatic dysfunction (serum ALT or serum AST > 2.5x upper limit of normal, or serum bilirubin elevated) Dosage: - dosage adjustment for serum AST or serum ALT elevation Monitor: - serum ALT, serum AST, & serum bilirubin at baseline & as needed during treatment (see contraindications) [5] Adverse effects: - fatigue (13%) - myalgia (8%) - mucositis (6%) - sensory neuropathy (28%) - motor neuropathy (1/23 patients) Mechanism of action: - microtubule stabilization - interaction with microtubules differs from taxanes - induces apoptosis

General

antimitotic agent; mitotic inhibitor (antineoplastic agent)

References

  1. Perez EA et al, Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407 PMID: 17606974
  2. Thomas E et al, Phase II clinical trial of ixbepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399 PMID: 17606975
  3. Dendeluri N et al Phase II trial of ixabepilone, en epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 2007, 25:3421 PMID: 17606971
  4. Roche H et al, Phase II clinical trial of ixbepilone (BMS-247550), an epothilone B analog, as first line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007, 25:3415 PMID: 17606972
  5. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: 260704 (subscription needed) http://www.prescribersletter.com